SubHero Banner

Polivy® (polatuzumab vedotin-piiq) – New indication

April 19, 2023 - Genentech announced the FDA approval of Polivy (polatuzumab vedotin-piiq), in combination with a rituximab product, cyclophosphamide, doxorubicin and prednisone (R-CHP), for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of two or greater.

Download PDF